ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2011
The galanin receptor 1 gene associates with tobacco craving in smokers seeking cessation treatment.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Distinct loci in the CHRNA5/CHRNA3/CHRNB4 gene cluster are associated with onset of regular smoking.Genetic epidemiology · 2013Pooled it
- Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Trial
- SNP analysis of stress-related genes reveals significant correlations with drug addiction in Jordan.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Involvement of Scratch2 in GalR1-mediated depression-like behaviors in the rat ventral periaqueductal gray.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Neuropeptide systems and new treatments for nicotine addiction.Psychopharmacology · 2017Review
- Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.Brain research · 2016Review
- Zinc Is Involved in Depression by Modulating G Protein-Coupled Receptor Heterodimerization.Molecular neurobiology · 2016Article
- Nicotinic acetylcholine receptors: upregulation, age-related effects and associations with drug use.Genes, brain, and behavior · 2016Review
- New mechanisms and perspectives in nicotine withdrawal.Neuropharmacology · 2015Review
- Drug addiction and stress-response genetic variability: association study in African Americans.Annals of human genetics · 2014Article
- Brain galanin system genes interact with life stresses in depression-related phenotypes.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Alteration of behavioral changes and hippocampus galanin expression in chronic unpredictable mild stress-induced depression rats and effect of electroacupuncture treatment.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Distinct features of neurotransmitter systems in the human brain with focus on the galanin system in locus coeruleus and dorsal raphe.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2012Review
- Comparative dynamics of four smoking withdrawal symptom scales.Addiction (Abingdon, England) · 2012Review
- The neuropeptide galanin and variants in the GalR1 gene are associated with nicotine dependence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Craving for tobacco is a major challenge for people with nicotine dependence (ND) who try to quit smoking. Galanin (GAL) and its receptors (GALRs) can alter addiction-related behaviors and are therefore good candidates for modulators of behavioral parameters associated with smoking. We performed a genetic association study in 486 subjects (432 European American, EA) recruited for smoking cessation trials. Twenty-six candidate genes for ND-related phenotypes were selected based on the literature. Subjects were assessed using the Minnesota Withdrawal Scale (MWS), which included a specific item for craving, the Fagerström Scale of Nicotine Dependence (FTND), and other ND-related instruments. One single-nucleotide polymorphism (SNP) in GALR1, rs2717162, significantly associated with severity of craving in EA samples (p=6.48 × 10(-6)) and in the combined sample (p=9.23 × 10(-6)). Individuals with TT and TC genotypes had significantly higher craving scores than CC subjects. We also observed that SNPs in the CHRNA5 locus, rs16969968 and rs684513, which have been associated with ND-related phenotypes in previous studies, were nominally associated with FTND scores, although these results did not meet Bonferroni-adjusted criteria for experiment-wide significance. Our findings suggest that variation at GALR1 associates with differences in the severity of past craving for tobacco among smokers motivated to quit. Taken together with preclinical evidence, these results, if replicated, suggest that GAL and GALRs may be useful therapeutic targets for the pharmacological treatment of ND. Our results also confirm previously reported associations between variation at CHRNA5 and ND.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.